Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;149(1):10-17.
doi: 10.1016/j.ajo.2009.08.038.

From the laboratory to the clinic: molecular genetic testing in pediatric ophthalmology

Affiliations

From the laboratory to the clinic: molecular genetic testing in pediatric ophthalmology

Arlene V Drack et al. Am J Ophthalmol. 2010 Jan.

Abstract

Purpose: To review the current state of molecular genetic testing as it relates to pediatric ophthalmology and to discuss its uses.

Design: Review and evaluation of available molecular genetic testing.

Methods: Literature review and discussion of testing in practice based on the authors' clinical and laboratory experience.

Results: Fee-for-service testing for many genetic eye diseases now is available. A report is always generated for fee-for-service testing. Detection of DNA variants in genes known to cause eye disease must be interpreted taking into account the variability of the human genome, the presence of benign variants (polymorphisms), and the carrier frequency of recessive alleles. Negative results in genetic testing are helpful in some disorders for which most of the causative genes are known and many disease-causing variants have already been reported, but are less helpful in those that currently have many undiscovered causative genes or novel mutations. Research-based testing also is available, but does not always yield a result. Patients with RPE65-associated Leber congenital amaurosis may be eligible for the current gene therapy trial. Patients with a variety of disorders may benefit from improved surveillance if their genetic diagnosis is known.

Conclusions: Entry into the genetic testing system often is via the patient's ophthalmologist. Collaboration with geneticists and genetic counselors, use of web sites to keep up with the ever-changing availability and detection rates, and knowledge of clinical trials, when combined with excellent clinical diagnosis, can improve diagnosis and allow eligible patients to participate in treatment trials.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Yandell DW, Campbell TA, Dayton SH, et al. Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. N Engl J Med. 1989;321(25):1689–95. - PubMed
    1. Berson EL, Rosner B, Sandberg MA, Dryja TP. Ocular findings in patients with autosomal dominant retinitis pigmentosa and a rhodopsin gene defect (Pro23His) Arch Ophthalmol. 1991;109(1):92–101. - PubMed
    1. Newman NJ, Biousse V. Hereditary optic neuropathies. Eye. 2004;18:1144–60. - PubMed
    1. Kondo H, Qin M, Tahira T, Uchio E, Hayashi K. Severe form of familial exudative vitreoretinopathy caused by homozygous R417Q mutation in frizzled-4 gene. Ophthalmic Genet. 2007;28:220–3. - PubMed
    1. Robitaille JM, Wallace K, Zheng B, et al. Phenotypic overlap of familial exudative vitreoretinopathy (FEVR) with persistent fetal vasculature (PFV) caused by FZD4 mutations in two distinct pedigrees. Ophthalmic Genet. 2009;30:23–30. - PubMed

Publication types